BEAM Chemotherapy: Combination Chemotherapy Regimens

BEAM chemotherapy is an acronym representing a small family of combination chemotherapy regimens that are used chiefly as salvage regimens in the context of Hodgkin's lymphoma that includes dexa-BEAM and mini-BEAM. They are also used as salvage or preparative regimens, some prior to stem cell transplantations.

BEAM Chemotherapy Drugs

The drugs that are in the standard BEAM chemotherapy are:

BCNU (carmustine)
Etoposide
Ara-C (cytarabine)
Melphalan

BEAM chemotherapy is an intense, high-dose six-day regimen that normally unrolls like this:

BEAM Chemotherapy Doses

Day 1: Carmustine (intravenous)
Days 2, 3, 4, 5: Etoposide (intravenous infusion); Cytarabine (intravenous infusion)
Day 6: Melphalan (intravenous)
Day 7: The patient undergoes the scheduled autologous stem cell transplantation

[Technically, the days should be numbered as a countdown; i.e. day 1= day -6, day 2=day -5 and so on until day 7, which equals day 0. I have done the opposite for easier understanding].

Dexa-BEAM Chemotherapy

Dexa-BEAM is an intense salvage chemotherapy regimen. The drugs used are as follows:

Dexamethasone
BCNU (carmustine)
Etoposide
Ara-C (cytarabine)
Melphalan

Dexa-BEAM chemotherapy unfolds as follows:

Cycle length: 28 days
Number of cycles: 2-4
Days 1-10: Dexamethasone (oral)
Day 2: BCNU (carmustine)
Day 3: Melphalan
Days 4-7: Etoposide (IV) & cytarabine (IV)

Mini-BEAM Chemotherapy

Mini-BEAM chemotherapy is a less dose-intense regimen that can be used as salvage chemotherapy or as a preparative regimen for a stem cell transplantation.

Cycle length: 28 days
Number of cycles: 2-4
Day 1: Carmustine
Days 2-5: Etoposide (IV); cytarabine (IV)
Day 6: Melphalan (IV)

If this regimen is used as a preparative regimen for a stem cell transplantation, the transplant would occur on the seventh day.

Sources

Boyiadzis, Michael M. et al. Hematology-Oncology Therapy. New York: McGraw Hill, Medical Publishing Division.

Perry, Michael C, Editor. Companion Handbook to the Chemotherapy Sourcebook. Baltimore; Williams & Wilkins.

Photo: Pexels

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap